Published in Cancer Chemother Pharmacol on March 20, 2008
5-Fluorouracil induced intestinal mucositis via nuclear factor-κB activation by transcriptomic analysis and in vivo bioluminescence imaging. PLoS One (2012) 1.07
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Oral mucositis: the new paradigms. Curr Opin Oncol (2010) 0.88
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol (2014) 0.88
IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol (2014) 0.87
5-Fluorouracil induces diarrhea with changes in the expression of inflammatory cytokines and aquaporins in mouse intestines. PLoS One (2013) 0.86
Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. BMC Gastroenterol (2012) 0.85
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget (2014) 0.82
Effect of low-level laser therapy on inflammatory mediator release during chemotherapy-induced oral mucositis: a randomized preliminary study. Lasers Med Sci (2014) 0.82
Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients (2013) 0.81
The effect of olive leaf extract in decreasing the expression of two pro-inflammatory cytokines in patients receiving chemotherapy for cancer. A randomized clinical trial. Saudi Dent J (2013) 0.80
Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. Exp Biol Med (Maywood) (2015) 0.79
Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation. Mediators Inflamm (2014) 0.78
New pathways for alimentary mucositis. J Oncol (2008) 0.77
Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis. J Pain Res (2011) 0.77
Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. Cancer Biol Ther (2012) 0.77
Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Support Care Cancer (2015) 0.77
Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. Eur J Clin Pharmacol (2016) 0.76
Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. World J Gastroenterol (2015) 0.76
Development of the rat model of lapatinib-induced diarrhoea. Scientifica (Cairo) (2014) 0.75
Association of tumor necrosis factor-α polymorphism with chemotherapy-induced oral mucositis in patients with esophageal cancer. Mol Clin Oncol (2016) 0.75
Effect of Hippophae rhamnoides Extract on Oxidative Oropharyngeal Mucosal Damage Induced in Rats Using Methotrexate. Clin Exp Otorhinolaryngol (2016) 0.75
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats. Cancer Chemother Pharmacol (2016) 0.75
The relationship between oral mucositis and levels of pro-inflammatory cytokines in serum and in gingival crevicular fluid in allogeneic stem cell recipients. Support Care Cancer (2014) 0.75
Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer (2007) 2.95
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer (2004) 2.29
Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol (2007) 2.24
Animal models of mucositis: implications for therapy. J Support Oncol (2011) 2.13
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer (2014) 1.93
Management of oral mucositis in patients who have cancer. Dent Clin North Am (2008) 1.72
Microarrays and clinical dentistry. J Am Dent Assoc (2003) 1.53
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27
Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity. Am J Physiol Renal Physiol (2013) 1.25
Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer (2006) 1.16
Swallowing dysfunction in cancer patients. Support Care Cancer (2011) 1.12
Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer (2006) 1.10
Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) (2009) 1.07
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther (2008) 1.06
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol (2003) 1.05
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis (2003) 1.04
Salen Mn complexes mitigate radiation injury in normal tissues. Anticancer Agents Med Chem (2011) 1.03
Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer (2005) 1.01
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer (2009) 1.01
Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol (2008) 1.00
Gastrointestinal mucositis. Semin Oncol Nurs (2004) 1.00
Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology (2005) 1.00
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci (2002) 0.99
Mucositis: pathobiology and management. Curr Opin Oncol (2015) 0.98
Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Cancer Res (2008) 0.98
Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis. Radiat Res (2014) 0.98
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther (2007) 0.96
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
A clinically translatable mouse model for chemotherapy-related fatigue. Comp Med (2013) 0.94
Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab (2009) 0.93
VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther (2007) 0.93
Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer (2013) 0.93
Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs (2008) 0.93
Chemotherapy-induced diarrhoea. Curr Opin Support Palliat Care (2009) 0.93
Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer (2014) 0.92
Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys (2005) 0.92
Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer (2014) 0.92
Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res (2003) 0.91
Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol (2012) 0.91
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol (2009) 0.91